Form 4: Director Corsee Sanders Sells Ultragenyx Shares

Director Corazon D. Sanders sold 2,000 shares of Ultragenyx Pharmaceutical Inc. common stock on June 15, 2026.

Summary

• Director Corazon D. (Corsee) Sanders executed a sale of 2,000 shares of Ultragenyx Pharmaceutical Inc. (RARE) common stock.
• The transaction occurred on June 15, 2026, at a price of $25.05 per share.
• Following this transaction, the reporting person maintains a direct beneficial ownership of 21,095 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a routine disclosure of an insider transaction without accompanying negative or positive strategic news.

Positives

• The transaction represents a standard divestment by an insider rather than a distress-related liquidation.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in near-term share price appreciation.

Risks

• The filing does not disclose specific company risks, as it is a standard Form 4 disclosure of insider trading activity.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this document.

Industry Context

StockSavvy.ai notes that insider sales are common in the biotechnology sector for liquidity or tax planning purposes and do not necessarily reflect a change in the company's fundamental outlook.

Comparison to Industry Standards

• Insider sales by directors are standard practice in the pharmaceutical industry and are subject to SEC reporting requirements.

Stakeholder Impact

• Minimal impact on shareholders as the sale volume is relatively small compared to total outstanding shares.

Key Dates

Keywords

Ultragenyx, RARE, Insider Trading, Form 4, Biotech, Director Sale